COST-EFFECTIVENESS ANALYSIS OF COMBINATION SALBUTAMOL-IPRATRORIUM AND SALBUTAMOL SINGLE IN PATIENTS ASTHMA OF DR. DRADJAT PRAWIRANEGARA SERANG HOSPITAL

Abstract

ackground: The treatment of asthma requires attention to achieve efficient and effective therapeutic outcomes. The most commonly used treatments for managing asthma attacks are single salbutamol therapy and the combination of salbutamol and ipratropium. 

Purpose: This research aimed to determine which treatment is more cost-effective between single salbutamol therapy and the salbutamol-ipratropium combination therapy for asthma patients at Dr. Dradjat Prawiranegara Hospital. 

Methodology: The study was conducted from a payer's perspective, with data collection done retrospectively using purposive sampling. Data were extracted from the medical records of asthma patients in the outpatient department of Dr. Drajat Prawiranegara Serang hospital for the period from January to December 2022. The pharmacoeconomic analysis used the Cost-Effectiveness Analysis (CEA) method. 

Results: The study included 12 subjects, consisting of 6 patients in the single salbutamol group and 6 patients in the salbutamol-ipratropium combination group. Based on the calculations, the Average Cost-Effectiveness Ratio (ACER) for the single salbutamol group was IDR 10,909, while the combination group was IDR 10,800. This indicates that the salbutamol-ipratropium combination group is more cost-effective compared to the single salbutamol group.